Convalescent Plasma in the Early Treatment of High-Risk Patients With SARS-CoV-2 (COVID-19) Infection

NCT04513158 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
2
Enrollment
OTHER
Sponsor class

Stopped Newly reported data at the time indicated that alternative therapies were more effective than CP for early treatment of high-risk patients with COVID-19.

Conditions

Interventions

Sponsor

Joseph M. Flynn, D.O., MPH